Partnerships are critical for many different industries, but they are especially critical when you’re trying to fundamentally change the clinical trial ecosystem. That’s why it’s exciting for Science 37 to announce its new partnership with UCB Biosciences to further the reach of decentralized clinical trials.
Here are some key benefits of the partnership that the two companies anticipate:
- Improved clinical trial experience for all
- Participation in UCB research studies will be more patient-friendly
- Research data will be more representative of real life
- Certain treatments may hit the market faster
Here’s what our CEO Noah Craft says about partnering with UCB: “We created Science 37 to uniquely combine telemedicine technology, decentralized physician networks and in-house experienced clinical study staff to take on new and exciting research studies. We are thrilled to join forces and collaborate with UCB for an even better, more realistic patient experience moving forward.”
Read the full announcement here.